Anorexia is a frequent part of uremic syndrome, contributing to malnutrition in dialysis patients. Many factors have been suggested as responsible for uremic anorexia.
A norexia is one of the most important causes of malnutrition in uremic patients (1) . Traditionally it is considered a sign of uremic toxicity and is used as a clinical marker to initiate dialysis or to define it as inadequate (2, 3) . In 1972 Babb et al. (4) proposed the "middle molecules hypothesis," which has maintained its popularity among nephrologists until the past few years. This hypothesis proposes that accumulation of middle molecules (between 300 and 5000 Da) may be responsible for several components of the uremic syndrome (5) . Anorexia is one of these symptoms. Recently, middle molecule fractions with the ability to inhibit appetite have been isolated (6) . However, the middle molecule hypothesis remains unproved and the compounds responsible for mediating anorexia are yet to be characterized (7) .
The "peak concentration hypothesis" (8) suggests that patients submitted to intermittent dialysis are subjected to variable levels of serum urea and other small molecule uremic toxins that may cause anorexia. In continuous treatments such as continuous ambulatory peritoneal dialysis (PD) and continuous cycling PD, the stable average concentration of uremic toxins is sufficiently higher than normal to explain toxicity. Many studies show a strong correlation between Kt/V and protein intake estimated by pro-PDI NOVEMBER 2000 -VOL. 20, NO. 6 HYPOTHESIS tein catabolic rate, but residual renal function seems to be more important for appetite control than dialysis dose itself (9, 10) . Moreover, it is not unusual to find patients with adequate dialysis parameters and (uremic) anorexia. This suggests that the accumulation or hyperproduction of other substances, or different uremic metabolic disorders, might be involved in (uremic) anorexia. This paper reviews current knowledge of the mechanisms controlling the hunger-satiety cycle in healthy people and its dysregulation in uremia.
REGULATION OF HUNGER-SATIETY
Food intake regulation implies a heterogeneous feedback system with various signals derived from the gastrointestinal (GI) tract and the liver, circulating nutrients, fat stores, and metabolizing cells, all transmitting information to the central nervous system (CNS). Input from the peripheral nervous system, including the vagus nerve and its gastric receptors, is also important. Signals are integrated in the CNS (central control of the appetite), inducing hunger or satiety. In the CNS, the hypothalamus contains the feeding center (lateral hypothalamus, dopaminergic activities) and the satiety center (ventromedial hypothalamus, serotonergic and adrenergic activities) (11) (12) (13) (14) .
PHASES OF FOOD INTAKE REGULATION
Gastric Phase: Food activates satiety signals in the GI tract. Two main factors are important in this phase: the meal volume (gastric distention) and meal composition. Protein and carbohydrates stimulate cholecystokinin (CCK) release, inducing satiety via decreasing gastric motility and central mechanisms (vagus nerve) (14, 15) .
Post Absorptive Phase: Satiety can be induced without the GI tract effect by intravenous infusion of nutrients (16, 17) . Several homeostatic theories, including glucostatic, lipostatic (leptin), and aminostatic (18, 19) , have been proposed to explain this phenomenon. These are particularly relevant in PD patients using glucose or amino acid solutions (18, 19) . In PD patients, abdominal distension induced by peritoneal fluid may play an important role in food intake control (20) . Thus, induced appetite suppression seems to be more marked with dialysis solutions with a high osmolarity. However, an increase in intragastric pressure has not been demonstrated in these patients (21) . Research by Mamoun et al. (21) showed that peritoneal solutions based on glucose and amino acid induce the inhibition of oral sucrose and protein intake in rats. These findings support the view that circulating nutrients, or their metabolic end-products, are able to regulate appetite by inducing gastrointestinal peptide (CCK, glucagon, and insulin) release.
Hepatic Phase: Several studies have demonstrated a physiologic role of the liver in appetite regulation, probably acting via vagal glucoreceptors. Intrahepatic adenosine triphosphate (ATP) concentration is recognized centrally via the vagus nerve (22, 23) . Cytokines have also been shown to play an important role in glucose and protein hepatic metabolic regulation (24) .
Central Phase: Signals from the GI tract and the liver reach the hypothalamus through two routes, peripheral nerves (mainly the vagus nerve) and the blood stream, as carbohydrates, amino acids, peptides, hormones, nitric oxide (NO), and cytokines. Two main neuropeptides, CCK, a recognized anorectic (15) , and neuropeptide Y (NPY), the most potent orexigen known (25, 26) , have been implicated in appetite control. Cytokines [tumor necrosis factor alpha (TNFα) and interleukin (IL)-1] are released during infection and malignant processes (27) . Nine TNFα molecular fragments have been isolated, each with a different action. The 69 -100 fragment has suppressive effects on food intake (28) . Interleukin-1 may also contribute to the anorectic effects of CCK and TNFα (29, 30) .
On the other hand, substances such as brain amino acids and NO have been implicated in peripheral and central appetite control. Changes in plasma amino acid profile participate in peripheral food intake control during the gastric (pre absorptive) phase. Amino acids induce satiety through the vagus nerve. Additionally, the contact between dietary amino acids and GI tract receptors stimulates CCK release (23, 31) . In the post absorptive phase, changes in plasma amino acid concentrations also induce satiety (16, 17) . Centrally, some amino acids can act as neurotransmitters, or precursors of a neurotransmitter, inducing hunger or satiety (32) . Catecholamine and serotonin pathways appear to be involved in the hypothalamic regulation of feeding. Catecholamine synthesis is influenced by brain levels of its precursor, tyrosine, and by its reaction end-products. Serotonin is synthesized in the brain from its precursor, tryptophan. Increases in brain serotonin activity are associated with a reduction in food intake. Two factors play a pivotal role in the regulation of eating behavior: the concentration of free tryptophan (not bound to albumin) (FTRP) and the molar ratio between FTRP and other plasma large neutral amino acids (LNAA), which are able to compete with tryptophan for brain entry (32, 33) .
Nitric oxide, an endothelium-released factor synthesized from the amino acid L-arginine by a specific synthase (NOS), participates in brain development and function. The administration of N G -nitro-L-arginine methyl ester (L-NAME), an inhibitor of NOS, reduces food intake in rats (34, 35) . Interesting observations have demonstrated an interaction between brain NO levels and serotonin synthesis (36) . Brain NO inactivates brain tryptophan hydroxylase (TPH), decreasing brain tryptophan and, subsequently, serotonin (37) and catecholamines. Both dopamine and norepinephrine increase the availability of brain tryptophan, forming a vicious cycle (38) . In uremia, NO deficiency has also been implicated in the pathogenesis of cardiovascular complications (39) . Possible disorders of the hunger-satiety cycle in uremic patients are listed in Table 1 .
In the following section we show the state of the art with respect to various appetite modulators in uremia, concentrating on serotonin as the central point of anorexia (Figure 1 ).
GASTROINTESTINAL PEPTIDES AND UREMIC A N O R E X I A
Cholecystokinin and other peptides are recognized anorectics having central and peripheral action (49) . Our group (50) and others (51) have demonstrated high plasma CCK levels in dialysis patients, due possibly to renal retention or hyperproduction. Our study also confirms lower NPY plasma levels in anorexic peritoneal dialysis patients. Importantly, some recent studies have shown that CCK increases hypothalamic serotonergic activity, possibly via the tryptophan pathway (51) . In contrast, NPY decreases brain serotonin levels, inducing hunger (32).
CYTOKINES AND UREMIC ANOREXIA Interleukin-1 and TNFα have been shown to interfere with tryptophan and serotonin turnover. It is therefore possible that IL-1 and TNFα participate in uremic serotonin-induced anorexia by interfering with the mechanism regulating the plasma tryptophan pool or by increasing brain serotonin release (27, 32, 52) . In support of this concept, several groups (42,50) have found high TNFα plasma levels in PD patients. TNFα plasma levels were found to be significantly higher in patients with anorexia and malnutrition (50) . Moreover, TNFα can inhibit hepatic albumin gene expression, contributing to dialysis protein malnutrition (53) .
NITRIC OXIDE AND UREMIC ANOREXIA Accumulation of an endogenous NO inhibitor, asymmetrical dimethyl-L-arginine (ADMA), has been described in uremic patients (44) . Experimentally, the administration of L-NAME increases blood pressure, induces gastric distention, increases brain serotonergic activity, and facilitates oxidation of L-arginine to ornithine (35, 36) . Also, TNFα decreases NOS levels through selective destabilization of mRNA transcript (54) , and increases the sympathetic activity, inducing anorexia again (55) .
Thus, the uremic NO deficiency could be another cause of anorexia via inactivation of brain TPH (37). (3, 35, 40, 41) Disturbances in peripheral and autonomic nervous system (axonal vagus nerve degeneration) Gastrointestinal tract motility disorders associated with peptides, TNFα, or uremia per se, and diabetic gastropathy Abdominal discomfort in peritoneal dialysis patients (3) Gastric distension associated with nitric oxide deficiency (35) 2 . Post absorptive phase (3) Peritoneal dialysis solution based on glucose or amino acids (peritoneal absorption) Inappropriate diets (rich in carbohydrates) 3 . Hepatic phase (42, 43) Disorders in metabolic hepatic glucose High cytokine plasma levels decreasing the production of hepatic ATP 4 . Central (brain) phase (11) (12) (13) (44) (45) (46) (47) (48) High plasma levels of surfeiters: peptides (CCK, glucagon, insulin, leptin, cortisol release factor, pancreatic polypeptide), cytokines (TNFα and IL-1), lower zinc and possibly NPY a Disorders in nitric oxide synthesis High FTRP (producing increase in serotonin synthesis) Imbalance in brain amino acids (high FTRP/LNAA ratio) 5 . Other causes: infections, medicaments, depression, poverty, alcohol abuse, rigorous diet before start of dialysis (3) TNFα = tumor necrosis factor alpha; ATP = adenosine triphosphate; CCK = cholecystokinin; IL = interleukin; NPY = neuropeptide Y; FTRP = free tryptophan (i.e., not bound to albumin); LNAA = large neutral amino acids. a Other group found high plasma levels. In our research, NPY was normal in 80% of cases, relatively low values were found in anorectic peritoneal dialysis patients. Leptin is produced by adipocytes that regulate the body-fat mass through a central satiety effect and has a molecular weight of 16 kDa. Hyperleptinemia has been described in uremia and may be due to uremic retention, hyperproduction, or both (56) . It has been suggested that leptin might be involved in the malnutrition of dialysis patients. On the basis of a leptin receptor disorder in the obese population and acquired leptin receptor disorders found in uremia (i.e., resistance to insulin or parathyroid hormone), we speculated that uremic anorectic patients may present a central satiety upregulation due to persistently high leptin levels. These patients may thus have normal sensibility to the hypothalamic leptin receptor (56) . Leptin induces appetite suppression by reducing the hypothalamic NPY levels and possibly by increasing sympathetic activity (45) . Consistent with this hypothesis is the sympathetic hyperactivity (i.e., dopamine, norepinephrine, serotonin) described in uremic patients (49, 57) . Moreover, in rats, the injection of leptin decreases brain nNOS, thyrotropin-releasing hormone, and corticotropin-releasing hormone mRNA in paraventricular and supraoptic nuclei (58) , with a consequent increase in the diencephalic serotonin content (59) .
PLASMA AND BRAIN AMINO ACIDS AND UREMIC A N O R E X I A
There is substantial evidence that changes in plasma amino acid profile affect brain or neurotransmitter synthesis (32) . A significant change in unbound plasma tryptophan and/or an increase of tryptophancompeting amino acids results in serotonergic hyperactivity and anorexia. These observations contribute to a tryptophan-serotonin hypothesis demonstrated in rats (32, 60) . A reduction in food intake in tumorbearing animals occurs in parallel with an increase in plasma FTRP/competing amino acid ratio and with an increase in tryptophan-serotonin brain content (61, 62) . A similar phenomenon has been identified in patients with cancer anorexia (32, 63) . These patients show a significant reduction in FTRP after curative surgery (32) . In contrast, an increase in FTRP plasma concentration appears 6 days after tumor cell inoculation in rats, and parallels tumor growth (32) . Also, changes in the central amino acid profile have been found in uremic humans and rats. They consist of low glutamine and GABA (gamma-amino-butyric acid); high glycine, free tryptophan (with reduced total plasma tryptophan), phenylalanine/tyrosine ratio, 5-hydroxyindoleacetic acid, homovanillic acid, and their ratios; and increases in alanine, lysine, arginine, histidine, 3-methyl-histidine, citrulline, and ornithine (64) (65) (66) . The evidence favors the possibility that hypothalamic serotonin has a greater effect in reducing carbohydrate ingestion in respect to protein or fat ingestion. However, chronic serotonin administration induces an important reduction of all macronutrients in experimental conditions. This supports the protagonist of serotonin in eating-disorder behavior (67, 68) .
The tryptophan/serotonin hypothesis (32) may apply to dialysis patients. In fact, the increase of plasma aromatic amino acid concentration, including tryptophan, and the reduction of neutral amino acids, with the consequent increase of FTRP/LNAA ratio, have been reported in uremic (64, 69) and cirrhotic patients (65) .
In summary, brain serotonin hyperproduction may be the final common pathway involved in the genesis of anorexia in dialysis patients (70) . An excess of serotonin substrate (FTRP) secondary to uremic amino acid disturbances would induce a poor response to appetite-stimulating peripheral signals. The variable expression of uremic anorexia could be the result of different combinations of changes in amino acid profile and peripheral appetite modulator status (CCK, NPY, leptin, cytokines, and NO).
According to this hypothesis, food intake might be increased by adopting the following measures:
1 . Blocking central serotonin receptors (32); 2 . Inhibiting brain serotonin reuptake (i.e., sertraline). However, this could produce a chronic increase in serotonin concentration as a consequence of receptor saturation, inducing a rebound phenomenon that causes anorexia (71). 3 . Reducing brain tryptophan availability with oral or parenteral administration of large neutral amino acids (LNAA) that compete for transport across the blood-brain barrier (Figure 1 ). This method has also been successfully tested in patients with cancer anorexia (62) . Combining this approach with serotonin reuptake inhibition might provide the best results. 4 . Modulating mechanisms responsible for FTRP increase. Unfortunately, up to now these mechanisms are still poorly understood.
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